|
Matters of the Mind
By
Beverly Moore |
Question:
I’ve been told the medications for Alzheimer’s don’t slow
the progression of the disease. Is this so? Why take them?
Answer:
The medications, Aricept, Reminyl, Exelon and Namenda are
available for those folks with dementia. The first three
boost the availability of acetycholine which helps brain
cells ‘talk to each other.’ Namenda works in a different way
and when given in combination they enhance one another.
It is true, that Alzheimer’s disease is not slowed down by
these medications. The damage caused by protein deposits in
the brain is still increasing. Brain cells are dying. What
these medications seem to do is help the remaining healthy
cells function better. What does this mean for the person?
They continue to do things easier than if they were not
taking the medications. Some caregivers also note that their
family member feels better; is in a more positive mood. If
the medication is stopped, the person loses ground
functionally and may not regain function even if put back on
the medications.
The prevailing opinion seems to be, then, that staying on
the medications keeps the person ‘doing’ longer; staying
actively engaged in everyday activities and staying in
relationship with others. Skills are lost, yes. But there is
much more to life than being skilled. Being loved and part
of a family is far better. |
About The Author
Beverly is owner of Alzheimer Coaching Services which
serves eastern Massachusetts and Rhode Island. ACS offers
coaching to understand dementia and learn how to keep the
person integrated into family life. Title III E Older
American Act grants provide free coaching to families in 45
towns and cities in the Bristol, south Norfolk, south shore
and West Suburban areas. No referral is necessary. There is
no restriction of income or age. Beverly’s company is
located in Quincy and she may be reached by calling (617)
233-1145 or visiting her web site at
www.alzheimercoachingservices. com.
Look for Beverly’s book “Matters of the Mind and the Heart”
to be released in early 2008 by Advantage Media Group.
|
|
